-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651.P1.114 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 10, 2022: 5:30 PM-7:30 PM
Hall D (Ernest N. Morial Convention Center)

Madelon M.E. de Jong, MD1*, Cathelijne Fokkema, MD1*, Natalie Papazian, BSc1*, Teddie van Heusden, BSc1*, Michael Vermeulen, BSc1*, Sabrin Tahri, MD1*, Remco Hoogenboezem, MSc1*, Mark van Duin, PhD1*, Pieter van de Woestijne, MD PhD2*, Anton Langerak, PhD3*, Annemiek Broijl, MD, PhD4*, Pieter Sonneveld, MD1 and Tom Cupedo, PhD1*

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands
3Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, Netherlands
4Erasmus MC Cancer Institute, Rotterdam, Netherlands

Lenka Besse, PhD1*, Andrej Besse1*, Sara C. Stolze2*, Amin Sobh, PhD3, Marianne Kraus1*, Hirofumi Nakagami2* and Christoph Driessen, MD1

1Laboratory of Experimental Oncology, Clinics for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2Protein Mass Spectrometry Group, Max Planck Institute for Plant Breeding Research, Cologne, Germany
3Department of Medicine, University of Florida, Gainesville, FL

Yun Dai, MD, PhD1, Xiaobo Liu, MS1*, Ting Yang, PhD1*, Shaji K Kumar, MD2 and Fengyan Jin, MD, PhD3

1Laboratory of Cancer Precision Medicine, The First Hospital of Jilin University, Changchun, China
2Department of Hematology, Mayo Clinic Rochester, Rochester, MN
3Department of Hematology, The First Hospital of Jilin University, Changchun, Jilin, China

Yuan Xiao Zhu, Ph.D.1*, Gregory J Ahmann, BS2, Laura Ann Bruins, BS2*, Mariano Arribas3*, Xianfeng Chen, PhD4*, Marta Chesi, PhD2, P. Leif Bergsagel, MD3, Rafael Fonseca2 and Lisa M. Rimsza, MD5

1Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
2Division of Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ
3Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ
4Department of Research Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ
5Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ

Filip Garbicz1,2,3*, Sonia Debek, MSc, BA1,4*, Anna Szumera-Ciećkiewicz, MD, PhD5*, Joanna Barankiewicz, MD6*, Dorota Komar, PhD4,7*, Michał Pawlak, PhD4*, Aleksandra Matrejek, MSc4*, Thorsten Stuehmer, PhD8*, Aleksander Salomon-Perzynski, MD6*, Agata Malenda, MD, PhD6*, Julia Ostrowska, MSc4*, Julia Dudkiewicz, MD9*, Krzysztof Brzózka, PhD10*, Tomasz Rzymski, PhD10*, Daniela Bellarosa, PhD11*, Ewa Lech-Marańda, MD, PhD12*, Monika Prochorec-Sobieszek, MD, PhD5*, Zofia Pilch, PhD13*, Dominika Nowis, MD, PhD13,14*, Jakub Golab, MD, PhD13,15*, Helen Tanton, PhD2*, Teru Hideshima, MD, PhD16, David M. Dorfman, MD, PhD17*, Irena Misiewicz-Krzeminska, PhD4*, Tomasz Sewastianik, PhD2,18*, Ruben D. Carrasco, MD, PhD2,19,20*, Maciej Szydlowski, PhD4* and Przemyslaw Juszczynski, MD, PhD4*

1Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland
2Department of Pathology, Dana-Farber Cancer Institute, Boston, MA
3Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Warszawa, Mazowieckie, Poland
4Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
5Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
6Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
7Centre for Omic Sciences (COS), Eurecat, Centre Tecnològic de Catalunya, Reus, Spain
8Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Wurzburg, Germany
9Department of Methodology, Medical University of Warsaw, Warsaw, Poland
10Ryvu Therapeutics, Cracow, Poland
11Experimental and Translational Oncology Department, Menarini Ricerche S.p.A., Pomezia (rome), AL, Italy
12Hematology Department, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
13Department of Immunology, Medical University of Warsaw, Warsaw, Poland
14Laboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, Poland
15Centre of Preclinical Research, Medical University of Warsaw, Warsaw, Poland
16The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
17Department of Pathology, Brigham and Women’s Hospital, Boston, MA
18Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Boston, MA
19Harvard Medical School, Boston, MA
20Department of Pathology, Brigham and Women's Hospital, Boston, MA

Doriana Gramegna1*, Na Liu2*, Yao Yao3*, Megan Johnstone4*, Domenico Maisano, PhD3*, Annamaria Gulla, MD5, Anil Aktas-Samur, PhD6*, Aldo Roccaro, MD, PhD7, Mehmet K. Samur, PhD8, Mariateresa Fulciniti, PhD8, Eugenio Morelli, MD9 and Nikhil C Munshi, MD, PhD10

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, BOSTON, MA
2Dana-Farber Cancer Institute, Boston
3Dana Farber Cancer Institute, Boston, MA
4Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
5Medical Oncology, Dana Farber Cancer Institute, Boston, MA
6DANA FARBER CANCER INSTITUTE, BOSTON, MA
7Department of Hematology, ASST Spedali Civili di Brescia, Brescia, BS, Italy
8Dana-Farber Cancer Institute, Boston, MA
9Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
10Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA

Adolfo Aleman, MPA1,2,3*, Ariel Kogan Zajdman4*, Yogita Ghodke-Puranik, PhD5*, Bhaskar Upadhyaya, PhD1,6*, Tarek H. Mouhieddine, MD7, Oliver Van Oekelen, MD, PhD1, Larysa Sanchez, MD1, Shambavi Richard, MD8, Adriana Rossi, MD, MSc1, Joshua Richter, MD1, Hearn J. Cho, MD, PhD1,7,9,10, Cesar Rodriguez, MD1*, Ajai Chari, MD11,12, Sundar Jagannath13,14,15 and Samir Parekh, MD1,6,16,17

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
3Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, NEW YORK, NY
4Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York
5Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY
6Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
7Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
8Icahn School of Medicine at Mt Sinai, Hematology/Oncology, Jersey City, NJ
9The Multiple Myeloma Research Foundation, Mount Sinai School of Medicine, New York, NY
10Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
11Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
12Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
13Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
14Center of Excellence for Multiple Myeloma, Mount Sinai Medical Center, New York, NY
15Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
16Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
17Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Shidai Mu, MD, PHD1*, Srikanth Talluri, PhD1*, Jiangning Zhao, PhD, MD1*, Lai Shi, PhD1*, Hannah Seah, MS1*, Lakshmi B. Potluri, MD1*, Jialan Shi, MD, PhD1, Mehmet K. Samur, PhD1, Masood A. Shammas, PhD1* and Nikhil C Munshi, MD, PhD2,3

1Dana-Farber Cancer Institute, Boston, MA
2Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA
3VA Boston Healthcare System, Boston

Romane Durand, PhD1*, Domitille Costes-Tertrais, MD1*, Geraldine Descamps, PhD1*, Christelle Dousset1*, Sophie Maïga1*, Jean-Baptiste Alberge, PhD1,2*, Elise Douillard1*, Jennifer Derrien, PhD1*, Celine Bellanger1*, David Chiron, PhD1*, Stephane Minvielle, PhD1*, Cyrille Touzeau1,3*, Philippe Moreau, MD1,3*, Martine Amiot, PhD1*, Patricia Gomez-Bougie, Pharm D, PhD1*, Agnes Moreau-Aubry, PhD1* and Catherine Pellat-Deceunynck, PhD1

1CRCI2NA, Integrated Research Center in Immunology and Oncology, Nantes University, Nantes, France
2Harvard Medical School, Boston, MA
3Hematology Department, Nantes University Hospital, Nantes, France

Catarina Maia1*, Noemi Puig, MD, PhD2,3, Cristina Pérez Ruiz4*, Maria Teresa Cedena Romero, MD, PhD5*, Camila Guerrero, MSc4*, Marta Larrayoz, PhD6,7*, Cirino Botta, MD, PhD8, Norma C. Gutierrez9,10*, María José Calasanz, PhD11*, Maria Luisa Martin-Ramos12*, Miguel Hernández13*, Laura Rosinol Dachs14*, Esther González Garcia, MD15*, Felipe De Arriba, PhD16*, Albert Oriol17*, Veronica Gonzalez-Calle, MD, PhD18*, Fernando Escalante, MD19*, Javier de la Rubia, MD20*, Mercedes Gironella Mesa, MD21*, Rafael Rios, MD, PhD22*, Ricarda Belen Garcia Sanchez23*, Jose Maria Arguiñano PEREZ24*, Adrian Alegre, MD25*, Jesus Martin, MD26*, María del Carmen Couto Caro27*, Maria Casanova, MD28*, Mario Arnao Herraiz, MD29*, Ernesto Pérez30*, Sebastián Garzón López31*, Marta Sonia Gonzalez Perez32*, Guillermo Martín-Nuñez33*, Adriana Rossi, MD, MSc34, Morton Coleman, MD35*, Cristina Encinas36*, Ana M. Vale37*, Ana Isabel Teruel, MD38*, María Cortés Rodríguez39*, Jose A. Martinez-Climent, MD6,40,41, Juan-José Lahuerta, MD, PhD42*, Joan Bladé Creixenti, MD, PhD43,44, Ruben Niesvizky, MD45, Jesús San-Miguel, MD, PhD4, Maria-Victoria Mateos, MD46,47 and Bruno Paiva4*

1Centro de Investigación Médica Aplicada, Clinica Universidad de Navarra, ) Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain, Pamplona, Spain
2Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
3Instituto Biosanitario de Salamanca (IBSAL) and Cancer Research Centre (Instituto de Biología Molecular y Celular del Cáncer; CSIC-USAL), Salamanca, Spain
4Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
5Department of Hematology, Hospital Universitario 12 de Octubre, CNIO, Madrid, Spain
6Department of Hemato-Oncology, University of Navarra, CIBERONC, IDISNA, Pamplona, Spain
7Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
8Department of Health Promotion, Mother and Child Care,Internal Medicine and Medical Specialties, University of Palermo, Italy, Palermo, Italy
9Hematology, Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, Salamanca, Spain
10Hospital Universitario de Salamanca,Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
11Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, Spain
12Hospital Universitario 12 de Octubre, Madrid, Spain
13Hospital Universitario de Canarias, Santa Cruz de Tenerife, La Laguna, ESP
14Hospital Clinic i Provincial, Barcelona, Spain
15Hospital Universitario de Cabueñes, Gijón, Spain
16Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
17Institut Català d’Oncologia and Institut Josep Carreras. Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
18Servicio de Hematologia, Hospital Universitario de Salamanca (CAUSA), Salamanca, Spain
19Hematology Department, Hospital Universitario de León, León, Spain
20Hematology Service Hospital La Fe and School of Medicine and Dentistry, Catholic University of Valencia, Valencia, Spain
21Department of Hematology, University Hospital Vall d’Hebron, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Spain, Barcelona, Spain
22Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain
23Complejo Hospitalario de Especialidades Virgen de La Victoria, Málaga, Spain
24Complejo Hospitalario de Navarra, Pamplona, Spain, Pamplona, ESP
25Hospital Universitario de La Princesa, Madrid, Spain, Madrid, Spain
26Hospital Universitario V. Rocio, Sevilla, Spain
27Hospital Universitario Virgen de Valme, Sevilla, Spain
28Hospital Costa del Sol Marbella, Marbella, Spain
29Haematology Department, Hospital Universitari i Politecni La Fe, Valencia, Spain
30Osakidetza Basque Health Service, Araba University Hospital,[Hematology department], Vitoria-Gasteiz, Spain
31Hospital del SAS de Jerez, Jerez De La Frontera, Spain
32Hospital Clinico Universitario Santiago, Santiago De Compostela, La Coruna, ESP
33Departamento de Hematología, Hospital Virgen del Puerto, Plasencia, Spain
34Icahn School of Medicine, Mount Sinai Hospital, New York, NY
35Division of Hematology & Medical Oncology, Weill Cornell Medical College, New York, NY
36Hospital Universitario Gregorio Marañó, Madrid, Spain
37CHUAC, A Coruña, Spain, Coruña, Spain
38Hospital Clínico Universitario de Valencia, VALENCIA, ESP
39Hematology Dept., Hospital Universitario de Salamanca, Spain, Salamanca, Spain
40Centre for Applied Medical Research (CIMA), Pamplona, Spain
41Department of Hemato-Oncology, Cima University of Navarra, Pamplona, Navarra, Spain
42Hospital Universitario 12 de Octubre; Instituto de Investigación Sanitaria Hospital Universitario 12 de Octubre i+12,H12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
43Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
44Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clínic, Barcelona, Spain
45Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
46Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
47Hematology Department, IBSAL-University Hospital of Salamanca. University of Salamanca, Salamanca, Spain

Sabrin Tahri, MD1,2*, Nang Kham Su, MS1*, Luisa Maria Lampe3,4*, Han Dong, PhD5, Juliana Vergara Cadavid1*, Natalie Papazian, BSc2*, Amanda Cao1*, Jean-Baptiste Alberge, PhD1*, Lucas Ferrari de Andrade, PhD6*, Mahshid Rahmat, PhD1*, Yujia Shen, PhD1,7*, Rebecca Boiarsky8,9*, Laura Blanco10*, Bruno Paiva11*, Andreas Guenther, MD12*, Gad Getz, PhD9*, Pieter Sonneveld, MD13, Tom Cupedo, PhD2*, Kai W. Wucherpfennig, MD, PhD14*, Irene Ghobrial, MD1 and Rizwan Romee, MD15

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
3Kiel University, Faculty of Medicine, Kiel, Germany
4Dana-Farber Cancer Institute, Boston, MA
5Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
6Department of Oncological Sciences, Icahn School of Medicine at the Mount Sinai Hospital, New York
7Department of Medicine, Yong Loo Lin School of Medicine, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
8CSAIL and IMES, Massachusetts Institute of Technology, Cambridge, MA
9Broad Institute of MIT and Harvard, Cambridge, MA
10University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Pamplona, Spain
11Clinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigación Medica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), Navarra, Spain
12Helios Kliniken Schwerin GmbH, Schwerin, Germany
13Erasmus MC Cancer Institute, Department of Hematology, Rotterdam, Netherlands
14Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA
15Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Nora Grieb1*, Jaren Sia2*, Jonathan Adam Scolnick, PhD2*, Shaun Cordes2*, Christina Kloetzer1*, Simone Heyn1*, Julia Strenge1*, Theresa Tumewu1*, Kristen Gerhardt1*, Kolja Nenoff1*, Anne Sophie Kubasch, MD3*, Song Yau Wang, MD1*, Enrica Bach, PhD1*, Madlen Jentzsch, MD1*, Georg-Nikolaus Franke, MD4*, Sebastian Schwind, MD4*, Klaus H Metzeler, MD1, Marco Herling, MD4*, Vladan Vucinic, MD4*, Uwe Platzbecker, MD5 and Maximilian Merz, MD4

1Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany
2Singleron Biotechnologies, Singapore, Singapore
3Department of Hematology, Cellular Therapy and Hemostaseology, Department of Hematology and Cell Therapy, Medical Clinic and Policlinic I, Leip, Leipzig, Germany
4Department for Hematology, Cell Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany
5Medical Clinical and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany

Neeraj Sharma, PhD1, Hongwei Tang, PhD2*, Huihuang Yan, PhD3*, Shulan Tian, MS, PhD4*, Suganti Shivaram, MBBS5*, Taxiarchis Kourelis, MD6, Shaji K Kumar, MD7 and Linda B. Baughn, Ph.D8

1Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
2Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
3Division of Computational Biology, Mayo Clinic, Rochester, MN
4Department of Health Sciences Research, Mayo Clinic, Rochester, MN
5Mayo Clinic, Rochester, MN
6Division of Hematology, Mayo Clinic, Rochester, MN
7Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
8Division of Laboratory Genetics, Mayo Clinic, Rochester, MN

Mary Sartor, BSc, PhD1*, David J Gottlieb, MD, MBBS, FRACP, FRCPA2* and Rosanne Dunn, PhD3*

1Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia
2Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, NSW, Australia
3Haemalogix Pty Ltd, Woolloomooloo, NSW, Australia

Haiming Chen, MD, PhD1, Eric Souther2*, Mingjie Li, BS1*, Marissa-Skye Goldwater, BS1*, Stacy Behare, BS1*, Ava Hekmati1*, Huixin Yu1*, Isabella Nassir1*, Ariella Nassir1*, Ning Xu, PhD1* and James R. Berenson, MD1,2,3

1Institute for Myeloma & Bone Cancer Research, West Hollywood, CA
2OncoTracker, West Hollywood, CA
3Berenson Cancer Center, West Hollywood, CA

Charlotte L.B.M. Korst1,2*, Wassilis S.C. Bruins, MD, MSc1,2*, Meliha Cosovic1,2*, Christie P.M. Verkleij, MD1,2*, Inoka Twickler1,2*, Diane Le Clerre3*, Isabelle Chion-Sotinel3*, Sonja Zweegman, MD, PhD1,2, Roman Galetto, PhD3*, Tuna Mutis, MD, PhD1,2* and Niels WCJ Van De Donk, MD1,2

1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands
3Cellectis SA, Paris, France

Denise Toscani, PhD1*, Oxana Lungu, MS1*, Vincenzo Raimondi, MS1*, Martina Chiu, PhD1*, Nicolas Thomas Iannozzi, MS1*, Jessica Burroughs Garcia2*, Anna Benedetta Dalla Palma, MD PhD3*, Matteo Scita, MD3*, Matia Bernardi, MD3*, Valentina Marchica, MS1*, Paola Storti, PhD1*, Ovidio Bussolati, MD, PhD1* and Nicola Giuliani, MD, PhD1,3

1Department of Medicine and Surgery, University of Parma, Parma, Italy
2Hematology and BMT Unit, University of Parma, Parma, Italy
3Hematology and BMT Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Murat Cem Köse1*, Margaux Lejeune2*, Marie Jia Gou3*, Elodie Duray3*, Gael Cobraiville4*, Jacques Foguenne5*, Andre Gothot6*, Yves Beguin, MD, PhD7, Mariane Fillet, Pharm8* and Jo Caers, PhD9,10

1Department of Hematology, University of Liege, Leuven, AL, Belgium
2Department of Hematology, University of Liege, Liège, BEL
3Department of Hematology, University of Liege, Liege, Belgium
4Laboratory for the Analysis of Medicines, University of Liege, Liege, Belgium
5University of Liege, Liege, BEL
6Department of Hematobiology and Immunohematology, University of Liege, Liege, BEL
7Department of Hematology, CHU Liege, University of Liege, Liege, Belgium
8Laboratory for the Analysis of Medicines, CIRM, University of Liège, Liège, Belgium
9Department of Hematology, CHU de Liège, Liege, Belgium
10University of Liege, Liege, Belgium

Djamila Chemlal1*, Emmanuel Varlet2*, Amelie Machura1*, Guilhem Requirand3*, Nicolas Robert3*, Elina Alaterre, PhD4*, Laure Vincent, MD5*, Charles Herbaux6, Giacomo Cavalli, PhD7*, Angélique Bruyer1*, Hugues De Boussac, PhD1* and Jerome Moreaux, PhD3,7,8

1Diag2Tec, Montpellier, France
2Institute of Human Genetic - CNRS, Montpellier, France
3Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France
4UMR CNRS-UM 9002, Institute of Human Genetics, Montpellier, France
5Department of Hematology, Montpellier University Hospital, Montpellier, France
6Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
7Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France
8UFR Médecine, Université Montpellier, Montpellier, France

Mahshid Rahmat, PhD1,2,3*, Michael Vinyard, MSc3,4,5,6*, Romanos Sklavenitis-Pistofidis, MD1,2,3, Kendell Clement, PhD7,8,9*, Elizabeth D. Lightbody, PhD1,2,3, Cody J. Boehner, BS10,11*, Laura Hevenor, BS2*, Jacqueline Perry, MPH1,2*, Gad Getz, PhD1,3,12,13,14* and Irene Ghobrial, MD1,2,3,15,16,17

1Department of Medicine, Harvard Medical School, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
3Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
4Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA
5Molecular Pathology Unit, Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA
6Department of Pathology, Harvard Medical School, Boston, MA
7Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA
8Broad Institute of MIT and Harvard, Cambridge, MA
9Harvard Medical School, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
11University of Massachusetts, Boston
12Center for Cancer Research, Massachusetts General Hospital, Boston, MA
13Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA
14Department of Pathology, Massachusetts General Hospital, Boston, MA
15Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
16Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
17The Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA

Shirong Li, PhD1, Jing Fu, PhD2, Jun Yang, MS3*, Huihui Ma, PhD3*, Markus Y. Mapara, MD4, Christophe Marcireau, PhD5* and Suzanne Lentzsch, MD, PhD3

1Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NJ
2Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
3Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
4Department of Medicine, Division of Hematology/Oncology, Columbia University College of Physcians and Surgeons, New York, NY
5Sanofi, Vitry sur seine, France

Umair Munawar, PhD1*, Xiang Zhou2*, Sabrina Prommersberger, PhD1*, Max Johannes Steinhardt1*, Julia Mersi, MD1*, Max Bittrich, MD1, Silvia Nerreter1*, Cornelia Vogt, MSc1*, Eva Teufel, MSc1*, Seungbin Han, MSc1*, Larissa Haertle3,4*, Patrick Eiring, PhD5*, Nicole Banholzer5*, Sophia Danhof, MD1*, Adrián Fernández-Martín, PhD3*, Marietta Truger6*, Santiago Barrio, PhD3,7*, Miguel Gallardo, PhD3*, Antonio Valeri, PhD3*, Eva Castellano3*, Peter Raab, MD8*, Claudia Haferlach, MD9, Markus Sauer, PhD5*, Michael Hudecek, MD1*, Joaquin Martinez-Lopez, MD PhD3*, Hermann Einsele, MD1, Leo Rasche, MD1* and Martin Kortuem1*

1Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
2Department of Internal Medicine II, University Hospital Wuerzburg, WüRzburg, Germany
3H12O-CNIO Hematological Malignancies Group, Clinical Research Unit. CNIO, Madrid, Spain
4Department of Internal Medicine II, Department of Internal Medicine II, University Hospital WüRzburg, W, WüRzburg, Germany
5Biotechnology & Biophysics Biocenter, University of Wuerzburg, Wuerzburg, Germany
6MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany
7Altum sequencing Co., Madrid, Spain
8Department of Orthopaedic Surgery, König Ludwig Haus, University of Wuerzburg, Wuerzbueg, Germany
9MLL Munich Leukemia Laboratory, Munich, Germany

Jonas Schwestermann1*, Andrej Besse, PhD1*, Serena Fazio2*, Cesar Nombela-Arrieta, PhD2*, Lenka Besse, PhD1* and Christoph Driessen, MD1

1Laboratory of Experimental Oncology, Clinics for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2Laboratory of Experimental Hematology, Clinics for Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland

Max Johannes Steinhardt1*, Patrick Eiring, PhD2*, Umair Munawar, PhD1*, Larissa Haertle3,4*, Seungbin Han, MSc1*, Cornelia Vogt, MSc1*, Silvia Nerreter1*, Eva Teufel, MSc1*, Julia Mersi, MD1*, Max Bittrich, MD1, Sophia Danhof, MD1*, Marietta Truger5*, Thomas Haaf, MD6*, Santiago Barrio, PhD3,7*, Xiang Zhou8*, Joaquín Martínez-López, MD, PhD3*, Claudia Haferlach, MD9, Michael Hudecek, MD1*, Hermann Einsele, MD1, Leo Rasche, MD1*, Markus Sauer, PhD2* and K. Martin Kortuem1*

1Department of Internal Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany
2Biotechnology & Biophysics Biocenter, University of Wuerzburg, Wuerzburg, Germany
3H12O-CNIO Hematological Malignancies Group, Clinical Research Unit. CNIO, Madrid, Spain
4Department of Internal Medicine II, Department of Internal Medicine II, University Hospital WüRzburg, W, WüRzburg, Germany
5MLL Munich Leukemia Laboratory, Inning am Ammersee, Germany
6Institute of Human Genetics, Julius Maximilians University, Wuerzburg, Germany
7Altum sequencing Co., Madrid, Spain
8Department of Internal Medicine II, University Hospital Wuerzburg, WüRzburg, Germany
9MLL Munich Leukemia Laboratory, Munich, Germany

Mohamed Shahin, BA1*, Charlotte Pawlyn, PhD2,3, Niels Weinhold, PhD4*, Timothy Cody Ashby5*, Brian A. Walker, PhD6, Christopher P. Wardell, PhD, MSc, BSc7*, David Cairns, PhD8*, Tom Menzies9*, Walter Martin Gregory, PhD9*, Martin F. Kaiser, MD, FRCP, FRCPath3,10, Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath9*, Mark T Drayson, MD11*, Roger G Owen12*, Graham Jackson, MBBS, FRCP, FRCPath, MA, DM13, Faith E Davies, MD14, Gareth J. Morgan, MD14 and John R Jones, MD15,16,17*

1Brighton and Sussex Medical School, Medical Student, Brighton, East Sussex, United Kingdom
2Institute of Cancer Research, Sutton, United Kingdom
3Royal Marsden Hospital, London, United Kingdom
4Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany
5Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, AR
6Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
7Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR
8Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, ENG, United Kingdom
9Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
10The Institute of Cancer Research, London, ENG, United Kingdom
11Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
12St. James's University Hospital, Leeds, United Kingdom
13Department of Haematology, University of Newcastle, Newcastle upon Tyne, United Kingdom
14Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
15Institute of cancer research, London, United Kingdom
16Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom
17King's College Hospital NHS Foundation Trust, London, United Kingdom

Wenzhuo Zhuang, MD, PhD1*, Shushu Yuan2* and Bingzong Li, MD, PhD3

1Department of Cell Biology, School of Biology & Basic Medical Sciences, Soochow University, Suzhou, China
2Department of Hematology, The second affiliated hospital of Soochow University, Suzhou, China
3Department of Hematology, The second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Wassilis S.C. Bruins, MD, MSc1,2*, Rosa Rentenaar, MSc1,2*, Sabrina Collins3*, James F. Sampson, PhD3*, Niels WCJ Van De Donk, MD1,2, Sonja Zweegman, MD, PhD1,2 and Tuna Mutis, MD, PhD1,2*

1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands
2Cancer Biology and Immunology, Cancer Center Amsterdam, Amsterdam, Netherlands
3Takeda Development Center Americas, Inc. (TDCA), Lexington, MA

Mateo Mejia Saldarriaga, MD1, David S Jayabalan, MSc2*, Aubrie Sowa1,3*, Jorge Monge, MD1, Cara A. Rosenbaum, MD1*, Roger Pearse, MD, PhD1, Ruben Niesvizky, MD1, Sanjay Patel, MD, MPH, MSc4 and Mark Bustoros, MD1

1Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
2Department of Pathology & Laboratory Medicine, Weill Cornell Medical College, New York, NY
3University College Dublin Medical School, Dublin, Ireland
4Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY

Asuka Shibamiya, MD, PhD1,2*, Naoya Mimura, MD, PhD1,3, Yurie Miyamoto-Nagai, MD, PhD1*, Shuhei Koide, PhD4*, Motohiko Oshima, PhD4*, Ola Rizq, MD, PhD4*, Kazumasa Aoyama, PhD4*, Yaeko Nakajima-Takagi, PhD4*, Kensuke Kayamori, MD, PhD1*, Yusuke Isshiki, MD, PhD1*, Nagisa Oshima-Hasegawa, MD, PhD1,3*, Tomoya Muto, MD, PhD1, Shokichi Tsukamoto, MD, PhD1, Yusuke Takeda, MD, PhD1*, Ryo Koyama-Nasu, PhD5,6*, Tetsuhiro Chiba, MD, PhD7*, Hiroaki Honda, MD, PhD8*, Koutaro Yokote, MD, PhD2*, Atsushi Iwama, MD, PhD4 and Emiko Sakaida, MD, PhD1,2,3

1Department of Hematology, Chiba University Hospital, Chiba, Japan
2Department of Endocrinology, Hematology, and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan
3Department of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan
4Division of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
5Department of Immunology, Chiba University Graduate School of Medicine, Chiba, Japan
6Department of Experimental-immunology, Chiba University Graduate School of Medicine, Chiba, Japan
7Department of Gastroenterology, Chiba University Graduate School of Medicine, Chiba, Japan
8Field of Human Disease Models, Major in Advanced Life Sciences and Medicine, Tokyo Women’s Medical University, Tokyo, Japan

David Sharon, PhD1*, Fengjiao Dunbar1*, Paul Jung, PhD1*, Xifeng Wang, PhD1*, Xiaotong Li, PhD1*, Christine Mantis, PhD1*, Orlando F. Bueno, MD, PhD1, Cyrille Touzeau2*, Philippe Moreau, MD3*, Simon J Harrison, MD4, Luciano J. Megala Costa, MD, PhD5, Jonathan L. Kaufman, MD6, Nizar J. Bahlis, MD7, Shaji K Kumar, MD8, Jeremy A. Ross, PhD1* and P.K. Epling-Burnette, PhD, PharmD1*

1AbbVie, Inc., North Chicago, IL
2Centre Hospitalier Universitaire (CHU) de Nantes, INSERM, Université de Nantes, Nantes, France
3Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
4Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
5University of Alabama at Birmingham, Birmingham, AL
6Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
7University of Calgary, Calgary, AB, Canada
8Mayo Clinic, Rochester, MN

Praneeth Reddy Sudalagunta, PhD1*, Mark B. Meads, PhD2*, Rafael Renatino-Canevarolo, PhD3*, Maria L. Coelho Siqueira Silva, MSc1*, Xiaohong Zhao, MD, PhD2*, Rhett Waldron4*, Christopher Cubitt, PhD5*, Raghunandan Reddy Alugubelli, MS6*, Gabriel De Avila, BS7*, Oliver Hampton, PhD8*, Robert Gatenby, MD, PhD9*, Rachid C. Baz, MD10, Kenneth H. Shain, MD, PhD2 and Ariosto Siqueira Silva, PhD1*

1Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3Cancer Physiology, H. Lee Moffitt Cancer Center, Tampa, FL
4Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
5Cancer PK/PD Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
6Collaborative Data Services Core, Moffitt Cancer Center, Tampa, FL
7Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
8M2GEN, Tampa, FL
9Diagnostic Imaging, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
10Department of Malignant Hematology, Moffitt cancer center and research institute, tampa, FL

Heather Fairfield, MS1,2,3*, Rebecca Condruti3*, Mariah Farrell2,3,4*, Reagan Di Iorio1,5*, Calvin Vary1,6,7*, Carlos A Gartner1,6,8* and Michaela R Reagan, PhD2,3,9

1MaineHealth Institute for Research, Scarborough, ME
2University of Maine, Orono, ME
3Tufts University School of Medicine, Boston, MA
4Maine Medical Center Research Institute, Scarborough, ME
5College of Osteopathic Medicine, University of New England, Biddeford, ME
6Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME
7Cell, Molecular and Developmental Biology, Tufts School of Medicine, Boston, MA
8Tufts University School of Medicine, Boston
9MaineHealth Institute for Research, South Portland, ME

Salsabil Ahmed, B.Pharm1*, Suman Mazumder, Ph.D1,2*, Lisa Wiesen3*, Neeraj Sharma, PhD4, Ujjal Kumar Mukherjee, Ph.D5*, Shaji K Kumar, MD6, Linda B. Baughn, Ph.D7, Brian G. Van Ness, Ph.D3 and Amit Kumar Mitra, PhD, MSc1,2

1Harrison College of Pharmacy, Auburn University, Auburn, AL
2Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Auburn University, Auburn, AL
3Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN
4Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
5University of Illinois - Urbana Champaign, Champaign, IL
6Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
7Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

Joshua P. Sasine, MD1, Jennifer Dukov1*, Dana Tran1*, Heather A Himburg, PhD2, Natalia Kozlova1*, Michelle Li3*, Jenny Kan2*, Mary Sehl, MD, PhD4*, Gary J. Schiller, MD5, Ritchie Ho, PhD6*, Brijesh Singh, PhD7*, Bryanna Reinhardt8*, Peibin Yue, PhD7*, Christina Termini, PhD9, Elena Pasquale, PhD10* and John P. Chute, MD1

1Department of Medicine, Division of Hematology and Cellular Therapy, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA
2Division of Hematology and Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA
3Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA
4Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles
5David Geffen School of Medicine at UCLA, Los Angeles, CA
6Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA
7Cedars-Sinai Medical Center, Los Angeles, CA
8Louisiana State University, New Orleans, LA
9University of Washington, Seattle, WA
10Sanford Burnham, La Jolla, CA

Eileen M Boyle, MD, MSc1, Patrick Blaney, MS1*, James Stoeckle, MD1*, Yubao Wang, PhD1*, Hussein Ghamlouch, PhD1*, Avital Tenenbaum1*, Ariel Siegel, MD1*, Xiaoyi Chen, MD, PhD1, Gaurav Varma, MD, MSPH1, David Kaminetzsky, MD1*, Marc Braunstein, MD, PhD2, Lydia Montes3*, Jill Corre4*, Even H Rustad, MD, PhD5*, Ola Landgren, MD6, Francesco Maura, MD7, Benedetto Bruno, MD, PhD8*, Aristotelis Tsirigos, PhD9*, Brian A. Walker, PhD10, Faith E Davies, MD11, Dylan Gagler, MS1* and Gareth J. Morgan, MD1

1Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
2Division of Oncology-Hematology, NYU Langone Hospital Long Island, Perlmutter Cancer Center, Great Neck, NY
3Hematology department, CHU Amiens, Amiens, France
4Toulouse, and CRCT, Toulouse, France, Toulouse, France
5Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
6Myeloma Division, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
7Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL
8Division of Hematology, Department of Molecular Biotechnology and Health Sciences, AOU Città della Salute e della Scienza di Torino, Turin, Italy
9Department of Applied Bioinformatics, New York University Langone Health, New York, NY
10Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
11Perlmutter Cancer Center, NYU Langone Health, New York, NY

Jing Li, MD1*, Yang Yang2*, Wenjing Wang, MD1*, Jiadai Xu, PhD1* and Peng Liu, MD1

1Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China
2Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China

Jean-Baptiste Alberge, PhD1,2,3*, Ankit K. Dutta, PhD1,3,4*, Elizabeth D. Lightbody, PhD1,3,4, Andrea Poletti, MSc1,3,4,5*, Andrew Dunford4*, Oliver Priebe4*, Julian M. Hess4*, Cody J. Boehner, BS1,3*, Romanos Sklavenitis-Pistofidis, MD1,3,4, Nang Kham Su, MSc1*, Erica Horowitz, BA1*, Hadley Barr, BA1*, Jenna B. Beckwith, MPH1*, Laura Hevenor, BS1*, Katherine Towle, BS1*, Jacqueline Perry, MPH1,3*, Esther Rheinbay, PhD4*, Chip Stewart, PhD4*, Gad Getz, PhD3,4,6* and Irene Ghobrial, MD1,3

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Department of Medicine, Harvard Medical School, Boston, MA
4Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
5"Seràgnoli" Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
6Center for Cancer Research, Massachusetts General Hospital, Boston, MA

Enze Liu, PhD1*, Nathan Becker, MS1*, Parvathi Sudha, MS1*, Chuanpeng Dong, PhD2,3*, Yunlong Liu, PhD4*, Jonathan J Keats, PhD5, Gareth J. Morgan, MD6 and Brian A. Walker, PhD1

1Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN
2School of Medicine, Yale University, West Haven, CT
3Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN
4Department of Medical and Molecular Genetics, Center for Medical Genomics, Indiana University School of Medicine, Indianapolis, IN
5Translational Genomics Research Institute, Phoenix, AZ
6Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY

*signifies non-member of ASH